Liver Cancer

Latest News
May 7th 2025

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

May 1st 2025

Elevated HLA-G Seen in HCC Driven by Viral Infections, Fatty Liver

April 29th 2025

New Developments Warrant Rethinking HCC Transplant Criteria

April 11th 2025

Nivolumab With Ipilimumab Approved by FDA for Use in Hepatocellular Carcinoma

March 21st 2025

Second CRL for Rivoceranib/Camrelizumab for Unresectable HCC

Video Interviews
View All
March 2nd 2025

Identifying Good Candidates for Histotripsy to Treat Liver Tumors

February 27th 2025

Lack of Long-Term Data, Insurance Coverage Impede Adoption of Histotripsy

February 23rd 2025

Histotripsy May Expand Beyond Liver Tumors, but Long-Term Data Are Still Needed

December 19th 2024

Using Ultrasound Waves to Destroy Liver Tumors

August 28th 2024

Health Care Bias, Cost of Care Biggest Barriers to Liver Care for LGBTQI+ Patients

August 1st 2024

Addressing Ongoing Disparities in Liver Cancer Care: Dr Amit Singal

May 28th 2024

Dr Amit Singal on How HCC Mechanisms Impact Treatment Approaches

May 8th 2024

Dr Michael Morse Discusses Gaps in Care Access, Equity in HCC

April 29th 2024

Dr Michael Morse on Managing Toxicities During HCC Treatment

April 25th 2024

Dr Amit Singal on Populations at Risk for HCC and When Screening Is Needed

More News

Top 5 liver cancer content of 2024 image graphic with health icons
December 27th 2024

Top 5 Most-Viewed Liver Cancer Content for 2024

Laura Joszt, MA
Advances in therapy are improving outcomes for patients, but the incidence and mortality rates for hepatocellular carcinoma are increasing in the US.
Doctor with human liver anatomy model | Image credit: Jo Panuwat D - stock.adobe.com
December 1st 2024

Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation

Megan Hollasch
Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment landscape for HCC.
Man holding liver illustration - SewcreamStudio - stock.adobe.com
November 26th 2024

Patients With HCC May Avoid Additional Treatment After Complete Response

Laura Joszt, MA
Patients with locally advanced hepatocellular carcinoma (HCC) who achieve a complete response after locoregional therapy and immunotherapy may be able to follow a watch-and-wait protocol.
Paper liver with a stethoscope | Image credit: filins - stock.adobe.com
November 24th 2024

Real-World Results of Durvalumab/Tremelimumab in U-HCC Show Promise Despite Line of Therapy

Laura Joszt, MA
Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable hepatocellular carcinoma (u-HCC).
Liver cancer | Image credit: Rasi - stock.adobe.com
November 21st 2024

FDA OKs Study of Amezalpat in Frontline Liver Cancer

Jordyn Sava
The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic hepatocellular carcinoma.
Woman holding a representation of a liver | Image credit: LIGHTFIELD STUDIOS - stock.adobe.com
November 14th 2024

Liver Cancer Risk Assessments: New Tool Beats Standard Screening

Laura Joszt, MA
A new risk score model for hepatocellular carcinoma using standard clinical data can better identify individuals at risk better than the current standard risk models.
AI models can be useful tools for clinicians, helping assess risk in patients with HCC to inform disease management. | Image credit: ipopba - stock.adobe.com
July 26th 2024

AI Model Precisely Identifies HCC Recurrence Risk Factors

Rose McNulty
Artificial intelligence (AI) models have potential to help clinicians assess risk in patients with hepatocellular carcinoma (HCC) to inform disease management, a new study found.
Illustration of liver cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
July 22nd 2024

Response to Immunotherapy Linked With Improved Liver Function in Advanced HCC

Rose McNulty
Although the amount of real-world evidence demonstrating the safety and efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma (HCC) has been growing, data on liver function evolution as a prognostic factor for overall survival are lacking.
Amit Singal, MD, medical director of the Liver Tumor Program at UT Southwestern Medical Center
July 10th 2024

Dr Amit Singal on Unmet Needs in HCC, Shifts in At-Risk Populations

Rose McNulty
While there have been advances in screening technology, it is crucial to continue investing in emerging modalities and to ensure these advancements translate to clinical practice.
A retrospective study aimed to determine whether adding PD-1 inhibitors to TACE plus lenvatinib improved the prognosis of patients with unresectable hepatocellular carcinoma. | Image credit: Crystal light - stock.adobe.com
July 3rd 2024

Study: Adding Anti–PD-1 to TACE Plus Lenvatinib Does Not Improve PFS in Unresectable HCC

Rose McNulty
The addition of PD-1 inhibitors to first-line treatment with transarterial chemoembolization (TACE) plus lenvatinib for hepatocellular carcinoma (HCC).
Woman holding liver representation | Image credit: LIGHTFIELD STUDIOS - stock.adobe.com
June 21st 2024

CBO Report Assesses Budgetary Effects of Potential Policies to Increase Hepatitis C Treatment

Rose McNulty
Health care spending avoided by increased hepatitis C treatment could more than offset direct spending on increased treatment, according to a new report from the Congressional Budget Office (CBO).
Liver cancer | Image Credit: Crystal light - stock.adobe.com
June 18th 2024

Promising Biomarker Predicts TARE Treatment Response in HCC

Karen Jacobson-Sive
The albumin-bilirubin score is a reliable predictor of treatment response for hepatocellular carcinoma (HCC) after yttrium 90 transarterial radioembolization (TARE).
Man holding liver illustration - SewcreamStudio - stock.adobe.com
June 12th 2024

Study Highlights Increasing Global Health Burden of Liver Cancer

Rose McNulty
The global burden of liver cancer is rising, and public health efforts for prevention, vaccination, and treatment to address underlying etiologies are needed, according to research presented at ASCO 2024.
Amit Singal, MD, UT Southwestern Medical Center
June 10th 2024

Dr Amit Singal on the Improving Outlook for HCC and How to Choose Treatments

Rose McNulty
Amit Singal, MD, medical director of the Liver Tumor Program at UT Southwestern Medical Center, discussed the current outlook for patients with hepatocellular carcinoma (HCC) and how to choose between therapies.
Hepatocellular carcinoma illustration | Image credit: Crystal light - stock.adobe.com
June 5th 2024

Camrelizumab Plus Rivoceranib Improves Survival vs Standard First-Line Care for HCC

Rose McNulty
In the final overall survival analysis of the phase 3 CARES-310 trial, frontline camrelizumab plus rivoceranib continued to show clinically meaningful survival benefits vs sorafenib for hepatocellular carcinoma (HCC).
Illustration of hepatocellular carcinoma | Image credit: Crystal light - stock.adobe.com
May 17th 2024

Screening Patients With HCC Risk Factors Linked With Reduced Mortality

Rose McNulty
A recent study found that screening for hepatocellular carcinoma (HCC) is associated with reduced mortality, highlighting the need to promote HCC screening for patients with known risk factors.
Molecule of DNA inside test tube illustration | Image credit: Connect world - stock.adobe.com
May 2nd 2024

Novel Blood Biomarkers Show Potential for Early Liver Cancer Diagnosis

Rose McNulty
A predictive model using plasma proteins as biomarkers predicted hepatocellular carcinoma development more accurately than a model based on traditional lifestyle risk factors in a recent study.
Liver cancer | Image credit: Rasi - stock.adobe.com
April 19th 2024

Real-World Data Show Racial Disparities in HCC Outcomes, Resource Utilization

Rose McNulty
The findings suggest there are ongoing disparities between Black and White patients with hepatocellular carcinoma (HCC) in terms of both outcomes and health care resource utilization.
Dr Michael Morse, Duke University
April 12th 2024

Dr Michael Morse on the Etiologies of HCC and Treatment Options for Patients With Worsening Liver Function

Rose McNulty
Michael Morse, MD, FACP, MHS, professor of medicine at Duke University School of Medicine and medical oncologist at Duke Cancer Center, discusses the etiologies of hepatocellular carcinoma (HCC) and how clinicians can tailor treatment for patients with varied levels of liver function.
Michael Morse, MD, FACP, MHS, Duke Cancer Center
April 5th 2024

Dr Michael Morse Discusses Current HCC Treatment Strategies and Future Directions

Rose McNulty
Michael Morse, MD, FACP, MHS, professor of medicine at Duke University School of Medicine and medical oncologist at Duke Cancer Center, spoke to the evolution of hepatocellular carcinoma (HCC) treatment in recent years, as well as ongoing research with potential to impact clinical practice.
AI in medicine | Image credit: ipopba - stock.adobe.com
April 5th 2024

Deep Learning Model Predicts Response to Combination Therapy Prior to Treatment in HCC

Rose McNulty
Researchers developed a web server that can help predict therapeutic responses to combination lenvatinib and immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma (HCC).
Machine Learning Model Predicts Hepatocellular Carcinoma Risk in Patients With MASLD
March 22nd 2024

Machine Learning Model Predicts Hepatocellular Carcinoma Risk in Patients With MASLD

Rose McNulty
Machine learning models have potential for early identification of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who are at risk of hepatocellular carcinoma.
Blue FDA approved stamp | Imaged credit: Olivier Le Moal - stock.adobe.com
March 14th 2024

FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis

Laura Joszt, MA
The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.
Man holding liver illustration | Image credit: SewcreamStudio - stock.adobe.com
March 10th 2024

Study Finds Increasing Hepatocellular Carcinoma Incidence, Mortality in the US

Rose McNulty
An analysis of nationwide data over 2 decades identified demographic-specific trends in liver cancer incidence and mortality in the US.
Nutritional Counseling - shidlovski - stock.adobe.com
March 8th 2024

Novel Assessment Accurately Predicts Nutritional Risk in Patients With HCC

Rose McNulty
A novel model for gauging nutritional risk among patients with hepatocellular carcinoma (HCC) showed high accuracy and may provide a simpler, more targeted alternative to currently used nutritional risk models used for patients with cancer.
Illustration of hepatocellular carcinoma - Crystal light - stock.adobe.com
February 28th 2024

Study Finds Distinct Tumor Microenvironment Characteristics in HBV-Related HCC

Rose McNulty
The analysis revealed that viral hepatocellular carcinoma (HCC) had a distinct microbial signature vs non-viral HCC, although only hepatitis B virus–related HCC showed a significantly diverse tumor microbiome.
Hepatocellular carcinoma illustration | Image credit: Crystal light - stock.adobe.com
February 21st 2024

Patients With Early vs Advanced HCC Show Distinct Gut Microbiota Alterations

Rose McNulty
Patients with early-stage hepatocellular carcinoma (HCC) and those with advanced-stage disease exhibited distinct gut microbiota diversity and alterations, with future studies warranted to investigate the mechanisms underlying the interactions between gut microbiota and HCC progression.
Dr Bruno Sangro Discusses Results for EMERALD-1 in Unresectable Hepatocellular Carcinoma
January 19th 2024

Dr Bruno Sangro Discusses Results for EMERALD-1 in Unresectable Hepatocellular Carcinoma

Produced by Mary Caffrey
The study’s senior author discusses how the combined mechanisms of action produced benefit in progression-free survival.
EMERALD-1: Durvalumab and Bevacizumab Plus TACE Improves PFS in Patients With Unresectable HCC
January 19th 2024

EMERALD-1: Durvalumab and Bevacizumab Plus TACE Improves PFS in Patients With Unresectable HCC

Mary Caffrey
One expert said the results have the potential to change the standard of care for some patients with the most common type of liver cancer.
ASCO GI logo
January 18th 2024

Camrelizumab With Chemo Before Surgery Shows Superior Responses Over Chemo in Locally Advanced ESCC

Mary Caffrey
The PD-1 inhibitor is being studied in multiple cancers; FDA is reviewing an application of a combination with rivoceranib in unresectable hepatocellular carcinoma.
12>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo